# Nomlabofusp PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nomlabofusp

> The next catalyst for nomlabofusp, sponsored by Larimar Therapeutics, Inc. (LRMR), is its primary completion, January 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | nomlabofusp |
| Codes | CTI-1601 |
| Sponsor | Larimar Therapeutics, Inc. (LRMR) https://sec-api.dev/companies/lrmr/catalysts |
| Indications | broad population of patients, [Friedreich Ataxia](https://sec-api.dev/indications/friedreich-ataxia) |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### Jan 2024: trial start

- Status: completed. Date confidence: month.
- First seen 2025-03-24, last confirmed 2026-03-19.
- SEC Form 10-K (accession 0001193125-26-115878): "In January 2024, we initiated the OL trial evaluating daily SC injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024." https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm
- SEC Form 10-K (accession 0000950170-25-043925): "In January 2024, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm
- SEC Form 10-Q (accession 0000950170-25-061222): "In March 2024, we dosed the first patient in the OLE trial, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver." https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-043925): "In March 2024, we dosed the first patient in our OLE trial, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm

### Feb 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-03-24, last confirmed 2025-04-30.
- SEC Form 10-Q (accession 0000950170-25-061222): "In February 2024, the Company reported positive top-line data and successful completion of the Phase 2 dose exploration study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm
- SEC Form 10-Q (accession 0000950170-25-061222): "In February 2024, we reported positive top-line data and successful completion of the Phase 2 dose exploration study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-043925): "In February 2024, we reported positive top-line data and successful completion of the Phase 2 dose exploration study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm
- SEC Form 10-K (accession 0000950170-25-043925): "In February 2024, the Company reported positive top-line data and successful completion of the Phase 2 dose exploration study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm
- SEC Form 10-K (accession 0000950170-25-043925): "In February 2024, we reported positive top-line data and successful completion of the dose exploration study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm

### December 16, 2024: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-12-16, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-136384): "Bala Cynwyd, PA, December 16, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA." https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/lrmr-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-26-076775): "In December 2024, we reported positive initial data from the ongoing OL study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver." https://www.sec.gov/Archives/edgar/data/1374690/000119312526076775/d28728d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-071493): "In December 2024, we reported positive initial data from the ongoing OL study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver." https://www.sec.gov/Archives/edgar/data/1374690/000119312526071493/d28728d424b5.htm
- SEC prospectus (424B) (accession 0001193125-25-169661): "In December 2024, we reported positive initial data from the ongoing OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver." https://www.sec.gov/Archives/edgar/data/1374690/000119312525169661/d942574d424b5.htm
- SEC Form 10-Q (accession 0000950170-25-061222): "In December 2024, the Company reported positive initial data from the ongoing OLE study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm
- SEC Form 10-Q (accession 0000950170-25-061222): "In December 2024, we reported positive initial data from the ongoing OLE study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-043925): "In December 2024, we reported positive initial data from our ongoing OLE study." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm

### March 24, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-03-24, last confirmed 2025-03-24.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-043487): "Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results" https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/lrmr-ex99_1.htm

### March 31, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 3.
- First seen 2025-04-30, last confirmed 2025-04-30.
- SEC Form 10-Q (accession 0000950170-25-061222): "The increase was primarily driven by an increase of $7.1 million in nomlabofusp manufacturing costs, an increase of $2.8 million in clinical costs primarily associated with the ongoing pediatric study which started and completed patient enrollment in the quarter ended March 31, 2025 and the start of our planned global Phase 3 study in the first quarter of 2025, an increase of $1.6 million in personnel expense due to increased headcount, and an increase of $1.2 million in consulting fees." https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-03-24, last confirmed 2025-04-30.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-060563): "In mid-2025 we expect to initiate our global Phase 3 study following global regulatory feedback on the study protocol, and we also expect to transition to the lyophilized formulation of nomlabofusp." https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-060563): "BLA Submission and Initiation of Global Phase 3 Study on Track: Global Phase 3 study is on track to initiate in mid-2025 with potential sites in the U.S., Europe, U.K., Canada, and Australia." https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-043487): "BLA Submission and Initiation of Global Phase 3 Study on Track: Larimar has obtained feedback from both FDA and EMA on the global Phase 3 study protocol and is on track to initiate the study by mid-2025 with potential sites in the U.S., Europe, U.K., Canada, and Australia." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/lrmr-ex99_1.htm

### Sep 2025: topline data readout

- Status: scheduled. Date confidence: month.
- First seen 2025-03-24, last confirmed 2025-04-30.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-060563): "Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025" https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-043487): "Topline 50 mg dose data from the OLE study and available data from the adolescent cohort of the PK run-in study planned for program update in September 2025" https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/lrmr-ex99_1.htm

### Sep 2025: interim data readout

- Status: scheduled. Date confidence: month.
- First seen 2024-12-16, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108409): "We have several important near-term catalysts ahead including initial data from the 50 mg dose of our open label study and data from the adolescent pharmacokinetic (PK) run-in study expected in September 2025." https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108409): "Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025" https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-136384): "Additionally, we are expanding clinical evaluation into adolescents with our recent initiation of our pediatric PK run-in study and expect initial data with the next update in mid-2025." https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/lrmr-ex99_1.htm

### Q4 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-18, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-136384): "BLA submission targeted for 2H 2025 Nomlabofusp (CTI-1601); FA: Friedreich's ataxia" https://www.sec.gov/Archives/edgar/data/1374690/000095017024136384/lrmr-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-127768): "BLA submission targeted for 2H 2025 Nomlabofusp (CTI-1601); FA: Friedreich's ataxia" https://www.sec.gov/Archives/edgar/data/1374690/000095017024127768/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-265702): "Process performance qualification (PPQ) on the commercial scale drug substance is planned in the fourth quarter of 2025, in preparation of data for BLA submission." https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-221538): "Process performance qualification (PPQ) on the commercial scale drug substance is planned in Q4 2025, in preparation of data for BLA submission." https://www.sec.gov/Archives/edgar/data/1374690/000119312525221538/d24800dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-060563): "Importantly, with the robust preclinical and clinical data package we have in hand and the additional clinical data readouts coming later this year, coupled with the positive FDA feedback and recommendations in line with our current approach, we are on track to submit our planned Biologics License Application (BLA) by the end of 2025 to seek accelerated approval," said Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar." https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm

### Q2 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-03-19, last confirmed 2026-05-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-222746): "Topline OL Study Data in Second Quarter of 2026: Larimar plans to report topline data from the OL study that is intended to support BLA submission in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-115119): "Topline OL Study Data in Second Quarter of 2026: Larimar plans to report topline data from the OL study that is intended to support BLA submission in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-115119): "In the second quarter of this year, we expect to report topline data from our open label (OL) study, as well as initiate screening in our global confirmatory Phase 3 study." https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm

### Jun 2026: trial start

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-02-24, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065186): "We continue to plan for a June 2026 BLA submission seeking accelerated approval and are excited to initiate our confirmatory Phase 3 study in the U.S., E.U., U.K., Canada and Australia." https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-115119): "Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026" https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065186): "Plan to initiate screening in global confirmatory Phase 3 study in Q2 2026; dosing of first patient expected mid-2026" https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-222746): "Global Confirmatory Phase 3 Study: Plan to initiate dosing of first patient mid-2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-115119): "Global Confirmatory Phase 3 Study: Plan to initiate screening in the second quarter of 2026, with dosing of first patient expected mid-2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-286780): "Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026" https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331516): "Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026" https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331516): "Global Confirmatory Phase 3 Study: Dosing of first patient expected Q3 2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-286780): "Dosing of first patient in global confirmatory Phase 3 study planned Q3 2026" https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-ex99_1.htm

### June 29, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Stage: 3. Indication: broad population of patients.
- First seen 2025-06-23, last confirmed 2026-08-04.
- SEC Form 8-K (accession 0001193125-26-286780): "On June 29, 2026, Larimar Therapeutics, Inc. (the "Company") issued a press release announcing (i) that it has submitted the first module of the Company's rolling Biologics License Application submission to the Food and Drug Administration for accelerated approval of nomlabofusp and (ii) positive data from the Company's ongoing long-term open label study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich's ataxia." https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-20260629.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-286780): "Bala Cynwyd, PA, June 29, 2026 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced it has submitted the first module of its rolling Biologics License Application (BLA) submission to the Food and Drug Administration (FDA) for accelerated approval of nomlabofusp; the remaining modules are expected to be submitted in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526286780/lrmr-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-331529): "We submitted the first module of our BLA to the FDA in June 2026 to request marketing approval of nomlabofusp." https://www.sec.gov/Archives/edgar/data/1374690/000119312526331529/lrmr-20260630.htm
- SEC Form 10-K (accession 0001193125-26-115878): "We are targeting to submit a BLA to the FDA in June 2026 for marketing approval of nomlabofusp using the accelerated approval pathway; however, there can be no assurance that the FDA will approve our BLA submission for accelerated approval." https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm
- SEC Form 10-K (accession 0001193125-26-115878): "We are targeting to submit a BLA to the FDA in June 2026 for marketing approval of nomlabofusp using the accelerated approval pathway; however, there can be no assurance FDA will approve our BLA submission for accelerated approval." https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm
- SEC prospectus (424B) (accession 0001193125-26-076775): "We are targeting to submit a BLA to the FDA in June 2026 for marketing approval of nomlabofusp using the accelerated approval pathway; however, there can be no assurance that the data from our clinical trials will ultimately support a BLA submission or that the FDA will grant marketing approval of nomlabofusp without additional clinical or nonclinical studies, or at all." https://www.sec.gov/Archives/edgar/data/1374690/000119312526076775/d28728d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-071493): "We are targeting to submit a BLA to the FDA in June 2026 for marketing approval of nomlabofusp using the accelerated approval pathway; however, there can be no assurance that the data from our clinical trials will ultimately support a BLA submission or that the FDA will grant marketing approval of nomlabofusp without additional clinical or nonclinical studies, or at all." https://www.sec.gov/Archives/edgar/data/1374690/000119312526071493/d28728d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-115119): ""Importantly, our ongoing engagement with the FDA reinforces our registrational path, and we remain on track to submit our Biologics License Application (BLA) seeking accelerated approval in June 2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065186): "The planned BLA submission is targeted for June 2026." https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065186): "We continue to plan for a June 2026 BLA submission seeking accelerated approval and are excited to initiate our confirmatory Phase 3 study in the U.S., E.U., U.K., Canada and Australia." https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-115119): "Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved" https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-065186): "Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved" https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-ex99_1.htm

### 2H 2026: NDA/BLA acceptance

- Status: scheduled. Date confidence: half.
- First seen 2026-08-04, last confirmed 2026-08-04.
- SEC Form 10-Q (accession 0001193125-26-331529): "We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026; however, there can be no assurance that we will submit the remaining modules on our expected timeline, that the FDA will accept the BLA for filing or the FDA will approve our BLA submission for accelerated approval." https://www.sec.gov/Archives/edgar/data/1374690/000119312526331529/lrmr-20260630.htm

### 2H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-05-14, last confirmed 2026-05-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-222746): "To facilitate a seamless review process, we continue to focus on the completeness of our chemistry, manufacturing, and controls (CMC) module, and plan to submit the CMC portion of the BLA in the second half of 2026," said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics." https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-ex99_1.htm

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Friedreich Ataxia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06447025 (An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06447025

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Friedreich Ataxia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06447025 (An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06447025

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Friedreich Ataxia; Friedreich's Ataxia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07778836 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07778836

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Friedreich Ataxia; Friedreich's Ataxia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07778836 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Larimar Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07778836

## Same indication

- [SKYCLARYS® (omaveloxolone)](https://sec-api.dev/pdufa/omaveloxolone) (BIIB)
- [Vatiquinone](https://sec-api.dev/pdufa/vatiquinone) (PTCT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nomlabofusp.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nomlabofusp PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nomlabofusp

```bibtex
@misc{secapidev_pdufa_nomlabofusp_20261116,
  title        = {Nomlabofusp PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nomlabofusp}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nomlabofusp_20261116","title":"Nomlabofusp PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nomlabofusp","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
